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Abstract
Background: Fibroblast growth factors FGF-1 and FGF-2 are often upregulated in tumors, but tightly bound to
heparan sulphate proteoglycans of the extracellular matrix (ECM). One mechanism of their bioactivation relies on the
FGF-binding protein (FGF-BP) which, upon reversible binding to FGF-1 or -2, leads to their release from the ECM. FGF-BP
increases tumorigenicity and is highly expressed in tumors like colon carcinoma. In this paper, we analyse cellular and
molecular consequences of RNAi-mediated FGF-BP knockdown in colon carcinoma, and explore the therapeutic effects
of the nanoparticle-mediated delivery of small interfering RNAs (siRNAs) for FGF-BP targeting.
Results: Employing stable RNAi cells, we establish a dose-dependence of cell proliferation on FGF-BP expression
levels. Decreased proliferation is mirrored by alterations in cell cycle distribution and upregulation of p21, which is
relevant for mediating FGF-BP effects. While inhibition of proliferation is mainly associated with reduced Akt and
increased GSK3b activation, antibody array-based analyses also reveal other alterations in MAPK signalling.
Additionally, we demonstrate induction of apoptosis, mediated through caspase-3/7 activation, and alterations in
redox status upon FGF-BP knockdown. These effects are based on the upregulation of Bad, Bax and HIF-1a, and
the downregulation of catalase. In a therapeutic FGF-BP knockdown approach based on RNAi, we employ polymer-
based nanoparticles for the in vivo delivery of siRNAs into established wildtype colon carcinoma xenografts. We
show that the systemic treatment of mice leads to the inhibition of tumor growth based on FGF-BP knockdown.
Conclusions: FGF-BP is integrated in a complex network of cytoprotective effects, and represents a promising
therapeutic target for RNAi-based knockdown approaches.
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Background
Fibroblast growth factors (FGF) represent a large poly-
peptide growth factors family comprising at least 23
members. Beyond embryonic development and tissue
repair in the adult, FGFs play important roles in cancer
and other diseases (see e.g. [1] for review). FGF-1 (acidic
FGF, aFGF) and FGF-2 (basic FGF, bFGF) are the best-
studied members and are often upregulated in tumors.
Since both are tightly bound to heparan sulphate pro-
teoglycans of the extracellular matrix (ECM), their
bioactivation in terms of release from the ECM is
required in order to allow their binding to FGF-recep-
tors. While tissue destruction or the digestion of the
HSPG sugar backbones by heparinases or other degrad-
ing enzymes may lead to enhanced FGF release under
certain circumstances, another mechanism relies on an
FGF-binding protein, FGF-BP1, acting as a chaperone
molecule for FGFs.
FGF-BP was first isolated from the supernatants of
A431 epidermoid carcinoma cells and termed HBp17
[2]. It is able to reversibly bind to FGF-1, -2, -7, -10,
and -22 [2-6], leading to reduced heparin affinity e.g. of
FGF-2 which is thus released from the extracellular
matrix [3,7,8]. FGF-BP is highly expressed in some
organs during embryonic development, but rapidly
downregulated thereafter [9]. In adult tissues, FGF-BP is
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Upregulation in carcinogenesis occurs already at early
stages of malignant transformation and is maintained
throughout development into invasive carcinoma [9-13].
In fact, several studies have demonstrated FGF-BP over-
expression in various tumors and tumor cell lines
including HNSCC, melanoma, cervix, prostate, mamma,
pancreatic and colon carcinoma [13-17]. Upregulation
of FGF-BP can occur, among others, by TPA through
Krüppel-like factor 5 (KLF-5) [18,19], DMBA [11], Wnt/
b-catenin signalling [12], HPV16 E6 [20], androgen
receptor activation [21] or EGF [22], while FGF-BP
downregulation has been described for retinoids [23-25],
TGF-b [26] or p53wt overexpression [27].
Supporting the functional relevance of FGF-BP in
tumors, its overexpression was shown to increase
tumorigenicity of FGF-BP-negative SW-13 cells, leading
to the formation of highly vascularized tumors in immu-
nodeficient mice [16,28]. Induction of angiogenesis was
also demonstrated in a chorioallantoic membrane assay
[3]. Concomitantly, ribozyme-mediated depletion of
FGF-BP led to reduced tumor growth and decreased
angiogenesis in SCC or prostate carcinoma cell lines
[15,29]. Taken together, these results established FGF-
BP as rate-limiting in tumor growth and as an ‘angio-
genic switch molecule’ (see [30] for review). While FGF-
BP exerts tumor-promoting effects through the activa-
tion of FGF-2 and activates FGF-2 [3,7], this does not
exclude additional functions other than enhancing FGF
activity, as suggested e.g. by the presence of FGF-BP in
the nucleus (Aigner et al., unpublished data).
In colon carcinoma, FGF-BP has been shown to be
upregulated in early dysplastic lesions of the human
colon as well as in primary and metastatic colorectal
cancers [12,13,29]. Stably ribozyme-transfected cells
indicated reduced tumor growth upon FGF-BP knock-
down and an inhibitory antibody led to reduced cell
proliferation in vitro [12,13,29].
In this paper, we identify several cellular and molecu-
lar consequences of RNAi-mediated FGF-BP knockdown
in colon carcinoma, and demonstrate that FGF-BP is
integrated in a complex network of cytoprotective and
proliferative effects. From these data and in vivo treat-
ment studies with polymeric nanoparticles for siRNA
delivery in s.c. colon carcinoma xenograft-bearing nude
mice, we also conclude that FGF-BP represents a pro-
mising therapeutic target, and establish RNAi-based
knockdown approaches through delivery of therapeutic
siRNAs for FGF-BP inhibition.
Methods
ShRNA constructs and generation of plasmids
shRNA expression vectors were constructed by annealing
synthetic complementary sense and antisense
oligonucleotides containing siRNA sequences against
hFGF-BP1 (NM_005130), a 9 nucleotide hairpin loop
sequence (TTCAAGAGA) and a RNA Pol III terminator
sequence tract (TTTTTT), flanked by a XhoI and a HindIII
site. The sequences of the shRNA constructs were as
follows:
FGF-BP “A” (mRNA 253-271):
5’GCACCCAGATTAAGCAGAAATTCAAGA-
GATTTCTGCTTAATCTGGGTGCTTTTTT-3’
FGF-BP “B” (mRNA 490-508):
5’GAGACATCTGTAGATATTCCTTCAAGAGAG-
GAATATCTACAGATGTCTCTTTTTT-3’
FGF-BP “C” (mRNA 364-382):
5’GGGTTGAGTGCACTCAATTGTTCAAGAGA-
CAATTGAGTGCACTCAACCCTTTTTT-3’
Firefly Luciferase shRNA (humanized, pGL3):
5’GTGCGCTGCTGGTGCCAACTTCAAGA-
GAGTTGGCACCAGCAGCGCACTTTTTT-3’
The annealed oligonucleotides were cloned into the pSin-
gle-tTS-Vector (Clontech) and the plasmids were checked
by sequencing for correct insertion. The luc3 shRNA and
the empty vector were used as negative controls.
Generation of stable mass-transfected and clonal cell lines
LS174T, HCT-116 and HT29 colon carcinoma cells
were obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA), HCT-116 p21 -/- were
obtained from Dr. Bert Vogelstein [31], and stable FGF-
BP expressing SW-13 adrenal carcinoma cells have been
described previously [16]. Cells were cultivated under
standard conditions (37°C, 5% CO2) in Iscove’s modified
Dulbecco’s medium (PAA Laboratories, Cölbe, Ger-
many) supplemented with 10% fetal calf serum (FCS)
unless indicated otherwise.
Stable transfections were performed in 60 mm Petri
dishes with 500,000 LS174T cells and 5 μg plasmid DNA
using TurboFect (Fermentas, St. Leon-Rot) or 200,000
cells (HCT-116, HT29) and 2 μg plasmid DNA using
Fugene (Promega, Mannheim, Germany) as described by
the manufacturers. Selection of stable integrants was
started 48 hours after transfection by adding 750 μg/ml
(LS174T) or 1000 μg/ml (HCT-116, HCT-29) G418
(PAA) for 2 weeks. In the case of HCT-116 p21-/- cells,
0.2 μg pcDNA 3.1/Hygro (Life Technologies, Darmstadt,
Germany) was added to the transfection, and stable cell
lines were selected in the presence of 800 μg/ml hygro-
mycin. Clonal selection from stably mass-transfected
cells was performed by clonal expansion, and stably mass
transfected cells or clonal shRNA expressing cell lines
were used as indicated in the experiments.
PCR and Quantitative RT-PCR (qRT-PCR)
The stable integration of the shRNA expression cassette
was confirmed by PCR analysis of genomic DNA with
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Pure PCR Template Preparation Kit according to the
manufacturer’s protocol (Roche Diagnostics, Mannheim,
Germany).
Total RNA from tumor xenografts or cells from tissue
culture was isolated using the TRI reagent (Sigma, Dei-
senhofen, Germany) according to the manufacturer’s
protocol. Reverse transcription (RT) was performed
using the RevertAid H Minus First Strand cDNA Kit
(Fermentas) with 1 μg total RNA and random hexamer
primers. Quantitative polymerase chain reaction was
performed using a LightCycler (Roche) in a total volume
of 10 μl per capillary containing 5 μl QuantiTect SYBR
Green 2× Master Mix, 4 μl diluted cDNA (1:50) and 1
μl intron spanning qPCR primers (5 μM each) specific
for FGF-BP or reference genes (b-actin, GAPDH). The
Hot Start Polymerase was activated by a 15 min pre-
incubation at 95°C, followed by 55 amplification cycles
at 95°C for 10 seconds, 55°C for 10 seconds and 72°C
for 10 seconds. CP values obtained were between 22
and 25 for FGF-BP and between 15 and 16.5 for actin/
GAPDH. A melting curve analysis was performed to
verify correct PCR products and a sample containing no
template was always run in parallel to control for back-
ground, which was at CP values > 50. Quantitation of
gene expression was performed by the ΔΔCt method
with b-actin and GAPDH serving as reference house-
keeping genes.
Western blot analysis
To determine the RNAi-mediated downregulation of
FGF-BP at the protein level, LS174T cells from cell cul-
ture were scraped and lysed in PBS/5 mM EDTA in
presence of Protease Inhibitors (’lysis buffer’) on ice, or
tumor xenograft tissue was homogenized in liquid nitro-
gen, and upon addition of lysis buffer treated by sonica-
tion or three freeze-thaw cycles. After centrifugation
and determination of the protein concentration in the
supernatant, samples containing 100 μg protein were
separated by SDS-PAGE (19% polyacrylamide containing
6 M Urea and a 10% Spacer Gel) and transferred onto a
nitrocellulose membrane (Protran Nitrocellulose Trans-
fer Membrane 0,45 μm Schleicher&Schuell, Dassel, Ger-
many) by semi-dry blotting. Membranes were blocked
with 5% milk powder in Tris-buffered saline + Tween
(TBST; 20 mM Tris, pH 7.5, 150 mM NaCl, and 0.1%
Tween-20) and incubated with either of the following
antibodies: 1:1000 rabbit polyclonal anti-FGF-BP raised
against a GST-human FGF-BP fusion protein [23,29],
1:5000 anti-HIF1a (Epitomics, Burlingame, CA), 1:2000
anti-catalase (Epitomics), 1:500 anti-p21 (Santa Cruz,
CA, USA), 1:250 anti-phosphoAkt (Santa Cruz) or
1:5000 anti-b-actin antibodies (Santa Cruz). The blots
were then washed in TBST and incubated with a donkey
anti-rabbit secondary antibody, diluted 1:2000 in TBST,
coupled to horseradish peroxidase (GE Healthcare Bio-
Sciences, Uppsala, Sweden) for 1 h at RT. After washing
in TBST, bound antibodies were visualized by chemilu-
minescence (ECL SuperSignal West Pico Kit, Thermo
Fisher Scientific, Rockford, IL, USA).
In vitro Proliferation and Growth Assays
Soft agar assays for the determination of anchorage-
independent proliferation and colony formation were
carried out essentially as described previously [32].
Briefly, 20.000 cells in 0.8 ml 0.35% agarose (Bacto Agar,
Becton Dickinson, Franklin Lakes, NJ) were layered on
top of 1 ml solidified 0.6% agar in a 6-Well plate.
IMDM/10% FCS was included in both layers. After 2
week, colonies > 50 μm were counted by at least two
independent investigators blinded to the study. Ancho-
rage-dependent proliferation of stable cells lines was
studied in triplicates using a WST-1 colorimetric assay
according to manufacturer’s protocol (Cell proliferation
Reagent WST-1, Roche) and as described previously
[33]. Briefly, cells were seeded into 96-Wells at 500 to
1000 cells per well and the proliferation rate was
assessed by determining the number of living cells at
each time point. For GSK3b inhibition, a 10 mM 6-bro-
moindirubin-3-oxime (BIO; Sigma, Deisenhofen, Ger-
many) stock solution in DMSO was diluted in medium
as indicated in the figure and added to the cells. For
FGF2 stimulation, recombinant FGF2 (NatuTec, Frank-
furt, Germany) from a 100 μg/ml stock solution was
added to the medium at the concentrations indicated in
the figure. Transient siRNA transfections in 96-wells
were performed using INTERFERin (PEQLAB, Erlangen,
Germany) and 1 pmol siRNA/well, prior to the WST-1-
based measurement of viable cells at the time points
indicated.
Apoptosis assays
To test for apoptosis in vitro, a commercially available
bioluminescent caspase-3/7 assay (Caspase-Glo
® 3/7
assay, Promega, Mannheim, Germany) and a fluoro-
metric Assay based on the caspase-3 substrate Ac-
DEVD-AMC (Alexis) were applied. The Caspase-Glo 3/
7 assay was performed in the 96-well format as recom-
mended by the supplier and luminescence was measured
after 1 hour incubation at 27°C in the dark using a
Fluostar Optima reader (BMG Labtec, Jena, Germany).
To normalize for differences in cell densities, a WST-1
assay was performed in parallel on the same plate, and
the results of caspase activity were adjusted to cell num-
bers of the different cell lines.
The Caspase-3 assay using Ac-DEVD-AMC was
assessed in a 6-Well format at a density of 100.000 cells.
At the time points indicated in the figures, cells were
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Cell lysis was performed in 300 μl lysis buffer (50 mM
Tris/HCl pH 7.4, 150 mM NaCl, 2 mM MgCl2,1 0m M
DTT and Protease Inhibitor (Protease Inhibitor Cocktail
Set III, Calbiochem)) followed by sonication in an ultra-
sonic bath three times for 10 sec. and chilling on ice.
Cellular debris was removed by centrifugation at 10,000
g for 5 min and the total protein content of the super-
natant was determined by a Bio-Rad protein assay. 30-
100 μg total protein was diluted in 40 μlo ff r e s h l yp r e -
pared reaction buffer containing PBS/10 mM DTT. 40
μl supernatant was transferred to 96 well plates (white
walled), the reaction was started by adding 10 μls u b -
strate solution (10 mM Ac-DEVD-AMC (Acetyl-Asp-
Glu-Val-Asp-7-Amino-4-methylcoumarin) stock solu-
tion in DMSO, dissolved in 500 μlP B S )t oaf i n a lc o n -
centration of 25 μM Ac-DEVD-AMC and measured
using a FLUOstar OPTIMA microplate reader (lex =
380 nm, lem = 475 nm). A background control contain-
ing the substrate in PBS/10 mM DTT without cell lysate
was run in parallel and a time curve of fluorescence was
measured at 37°C every 20 min to check for linearity.
Averages of triplicates were subtracted from the back-
ground signal and values were normalized as x-fold
increase in apoptosis rate relative to the corresponding
values of control cells at time points indicated in the fig-
ures. Cells treated with 50 μg/ml 5-fluorouracil served
as positive control.
Analysis of differential gene expression by Phospho-MAP
Kinase and Apoptosis Antibody Array Kits
The activity of a panel of mitogen-activated protein
kinases (MAPKs) and other serine/threonine kinases
was assessed through the determination of their relative
levels of phosphorylation using the Proteome Profiler
A r r a y( R & DS y s t e m s ,W i e s b a d e n ,G e r m a n y )a c c o r d i n g
to the manufacturer’s instructions. Briefly, stable FGF-
BP depleted cells and control cells were seeded at 50%
confluency in 6-well plates and grown for 2 days prior
to lysis at 1 × 10
7 cells/ml in lysis buffer for 30 minutes
at 4°C. After centrifugation at 14,000 g for 5 minutes,
the protein concentration of the supernatant was deter-
mined, and the volume of each sample equivalent to
250 μg of protein was diluted in Array Buffer 1 to yield
a final volume of 1.5 ml. Arrays were pre-incubated in
1.5 ml Array Buffer 1 for 1 hour before incubating the
array strips in the diluted sample at 4°C overnight,
washing 3 × 10 minutes in 20 ml wash buffer, incubat-
ing in the detection antibody cocktail (1:100 in 1X
Array Buffer 1), washing, and incubating in a Streptavi-
din-HRP solution (1:2000). After washing again, signals
were developed by incubating in a chemiluminescent
substrate (SuperSignal West Femto Kit, Thermo Fisher
Scientific, Rockford, IL), and chemiluminescence was
visualized by film exposure (Hyperfilm ECL; GE Health-
care, Munich, Germany). To precisely analyze very
strong as well as very weak signals within the linear
range, exposure times were varied between 5 seconds
and 2 minutes. Signals were scanned and quantitated by
densiometry using ImageJ (National Institutes of Health,
Bethesda, MD).
Analysis of cell cycle distribution
For flow cytometry-based analysis of cell cycle distribu-
tion, the sample preparation and propidium iodide
staining of nuclear DNA were performed as described
previously [34]. Briefly, 200.000 cells were grown at
~50% confluency, harvested by trypsinization, washed
twice with PBS and fixed in 70% ethanol diluted in PBS
at -20°C for 1 h. The cells were resuspended in PBS and
incubated with 100 μg/ml RNAse in PBS at 4°C over-
night, prior to addition of 40 μg/ml propidium iodide
and analysis by flow cytometry. To monitor FGF-BP-
dependent effects on cell cycle, cells were arrested in
the G2/M phase by pre-treatment with 250 ng/ml noco-
dazole (750 nM) for 24 h. The cells were then either
harvested and processed as described above, or washed
twice with PBS and further cultivated in fresh medium
for another 24 h to release the nocodazole-induced
mitotic cell cycle arrest prior to cell cycle analysis. Dis-
tribution of cell cycle was determined using a FACS
Calibur (Becton-Dickinson) with an argon laser set to
excite at 488 nm and measuring FSC, SSC, peak width
and area of fluorescence. Counts were gated to exclude
aggregates and subcellular debris, and from a minimum
of 20,000 gated events for each sample, a frequency his-
togram of peak areas was generated and analysed using
Cell-Quest software.
Subcutaneous tumor xenograft model in nude mice
Effects of RNAi-mediated FGF-BP knockdown on
LS174T tumor growth in vivo was determined by treat-
ing subcutaneous tumor xenograft-bearing mice with
siRNAs complexed with polyethylenimine (PEI) as
described previously [35]. 5 × 10
6 LS174T wildtype cells
were injected subcutaneously into both flanks of athy-
m i cn u d em i c e( C r l : C D 1 - F o x n 1 n u ,C h a r l e sR i v e r
Laboratories, Sulzfeld, Germany). When solid tumors
were established after 5 days, mice were randomized
into treatment or control groups with 6-8 animals per
group. Mice in the specific treatment group were
injected intraperitoneally (i.p.) with 0.77 nmol (10 μg)
FGF-BP-specific siRNA duplexes (5’-GCCAGAGU-
GAUAAUUUCAGTT-3’/5’-CUGAA AUUAUCACU-
CUGGCTC-3’), complexed with PEI F25-LMW as
described previously [35,36], every 3 times per week for
4 weeks. PEI F25-LMW-complexed non-specific siRNA
(pGL3; 5’-CGUACGCGGAAUACUUCGATT-3’/5’-
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same manner, as well as untreated mice served as nega-
tive controls. Tumor volumes were measured three
times per week as indicated in the figure. Upon termina-
tion of the experiment, mice were sacrificed and tumors
were removed. Pieces of each s.c. tumor xenograft were
immediately shock frozen for preparation of RNA or of
protein.
For the radioactive determination of siRNA delivery
into the tumor, 0.6 μg (0.05 nmoles) FGF-BP-specific
siRNAs were [
32P] end-labeled at both strands using T 4
polynucleotide kinase and g-[
32P] ATP. To remove
unbound radioactivity, siRN A sw e r ep u r i f i e db ym i c r o -
spin columns (Bio-Rad, München, Germany) and com-
plexed prior to i.p. injection as described above. After 2
h, mice were sacrificed and tumors were removed for
RNA preparation as described above. The total RNA
was dissolved in 200 μl DEPC-treated water, and 10 μl-
samples were mixed with loading buffer, heat-denatured
and subjected to agarose gel electrophoresis prior to
blotting and autoradiography (Biomax, Eastman-Kodak,
Rochester, NY). Quantitation was performed by phos-
phor imager analysis.
Animal studies were conducted according to guide-
lines of animal welfare and approved by the Regierung-
spräsidium Giessen.
Statistics
Statistical analyses were performed by Student’st - t e s t ,
One-way ANOVA/Tukey’s multiple comparison post-
tests or Two-way ANOVA using GraphPad Prism4, and
significance levels are * = p < 0.05, ** = p < 0.01, *** = p
< 0.001, # = not significant. Values are shown +/- s.e.m.
Results
RNAi-mediated FGF-BP knockdown exerts ‘gene dose-
dependent’ anti-proliferative effects in colon carcinoma
cells in vitro
LS174T cells were stably mass transfected with shRNA
expression plasmids and, upon generation of G418-resis-
tant cells, clonal selection was performed through lim-
ited dilution. The analysis of FGF-BP expression levels
in various clonal cell lines by qRT-PCR demonstrated
the functionality of all three shRNAs as compared to
control-shRNA or non-transfected cells, with residual
mRNA levels in clonal cell lines being between 20% and
> 90% (data not shown). For subsequent experiments,
three clones (A3, B8, C11) were selected, which are
based on the different shRNAs and showed stable
knockdown efficacies of 60-80% (Figure 1A). The paral-
lel use of three clonal cell lines stably transfected with
different shRNAs, and the comparison between non-spe-
cific shRNA and wildtype cells, also allows to control for
off-target effects specifically based on a certain sequence
(see e.g. [37] for review) or non-specifically based on
increased shRNA expression [38]. Knockdown efficacies
in the stable cell lines were confirmed on protein levels
by Western blotting and revealed an RNAi-mediated
reduction of FGF-BP protein by ~ 50% (A3) to > 80%
(C11) (Figure 1B).
When cells were analysed in proliferation assays, a sig-
nificant reduction in anchorage-dependent proliferation
was observed upon shRNA-mediated FGF-BP knock-
down vs. negative controls (non-specific shRNA (’mock’)
transfected cells or wt cells). More specifically, the ~ 8-
fold proliferation rate over 5 d in the control cells was
reduced to ~ 5-fold upon 50% FGF-BP knockdown, to ~
3-fold upon 60% FGF-BP knockdown, and to ~ 2-fold
upon 80% knockdown (Figure 2A). Strikingly, the com-
parison between the different clonal cell lines also
revealed that the anti-proliferative effects were directly
correlated with residual FGF-BP protein levels (Figure
2B; r
2 = 0.94). Thus, this establishes an FGF-BP gene
dose effect on LS174T cell proliferation, further sup-
porting the functional relevance of FGF-BP on LS174T
colon carcinoma cell growth.
The anti-proliferative effects of FGF-BP knockdown
were confirmed in soft-agar assays, which monitor the
anchorage-independent growth and thus resemble more
closely the in vivo situation. Here, however, the 50%
FGF-BP knockdown resulted already in a substantial >
70% reduction in colony formation over wt control cells
(with negative control shRNA-transfected cells showing a
slight reduction in colony numbers as well), with no
further decrease in colony formation being observed in
the cell lines with lower FGF-BP levels (Figure 2C). More
specifically, FGF-BP knockdown, independent of residual
FGF-BP levels, resulted in smaller-sized colonies and
smaller colony numbers (Figure 2C, upper panel). This
suggests that LS174T cells growing under anchorage-
independent conditions are even more dependent on
FGF-BP expression than when cultivated on plastic, and
further emphasizes the possible relevance of FGF-BP as
therapeutic target for knockdown approaches in vivo.
The rate-limiting effect of FGF-BP on cell growth was
further confirmed in other colon carcinoma cell lines.
FGF-BP knockdown in HT29 cells revealed a ~ 20-60%
reduction of soft agar colony formation (Figure 2D).
Likewise, profound > 50% antiproliferative effects were
observed in anchorage-dependent proliferation (Figure
2E, left) and anchorage-independent soft agar colony
formation upon transfection of HCT-116 cells with
FGF-BP shRNA (Figure 2E, right).
FGF-BP knockdown leads to alterations in cell cycle and
induction of apoptosis
To analyse the effects of FGF-BP knockdown on LS174T
colon carcinoma cell growth in more detail, the various
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compound for mediating G2/M arrest, 20 h prior to cell
cycle analysis by propidium iodide staining and flow cyto-
metry. In wt and negative control-transfected cells, the
FACS-based cell cycle analysis revealed a profound noco-
dazole-mediated G2/M arrest (Figure 3, upper panel, left).
In contrast, upon FGF-BP knockdown the nocodazole-
mediated M-trapping was markedly reduced, indicating a
slower cell cycle progression which results in a smaller
fraction of cells being in the G2/M arrest after 20 h.
Again, this effect was ‘FGF-BP gene dose-dependent’ with
the deceleration in cell cycle progression being more pro-
found in clone B8 vs. clone A3 cells (Figure 3A, lower
panel). Notably, FGF-BP knockdown also resulted in a
marked increase in the sub-G0 population, which is asso-
ciated with apoptosis. Again, this effect was more pro-
found in the B8 clone (Figure 3A, right).
To further analyse the effect of decreased FGF-BP
expression on apoptosis, caspase activity was measured in
the various stable cell lines in a caspase-3/7 assay. As com-
pared to the negative control cells, a ~ 2-fold increase in
caspase-3/7 activity was observed upon FGF-BP knock-
down (Figure 3B, left). A slight but not significant trend
towards higher apoptosis was observed in the clone C11
with the lowest FGF-BP levels. Likewise, a ~ 1.3 increase
in apoptosis was observed in FGF-BP shRNA-transfected
HCT-116 cells (Figure 3B, right). This establishes for the
first time, and in contrast to previous results in other cell
lines [15], that human FGF-BP exerts anti-apoptotic
effects. For further analysis, we tested a reverse setting by
overexpressing FGF-BP. In LS174T cells, no further reduc-
tion of apoptosis below levels in negative control cells was
observed, indicating that the forced expression of FGF-BP
did not add an effect beyond the anti-apoptotic effect of
the FGF-BP (over-) expressed physiologically in this cell
line (Figure 3C, left). This finding was independent of the
cultivation conditions, i.e. the serum concentration in the
medium (between 0% and 10%; data not shown). In con-
trast, the forced expression of FGF-BP in the adrenal car-
cinoma cell line SW-13, which is physiologically FGF-BP-
negative, led to a significant ~ 40% reduction in the intrin-
sic apoptosis rate indicating an ‘apoptosis rescue’ upon
FGF-BP overexpression (Figure 3C, right).
Anti-proliferative effects of FGF-BP knockdown are based
on alterations in phospho-MAPK status
To analyse the anti-proliferative effects of FGF-BP inhi-
bition in more detail on the molecular level, the activity
of various downstream signal transduction molecules
was monitored through the determination of their
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Figure 1 RNAi-mediated knockdown of FGF-BP in LS174T colon carcinoma cells. LS174T cells stably mass-transfected with shRNA expression
plasmids and clonally selected show reduced FGF-BP expression as determined on mRNA (qRT-PCR, A) and protein level (Western blot, B).
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antibody array. Signal intensities in negative control-
transfected (’mock transfected’) cell lysates were com-
pared to lysates of the cells with the most profound
knockdown, i.e. clone C11. Since signal intensities varied
over a broad range dependent on the analyte dotted on
the membrane, several exposures were scanned to
ensure that only signals in the linear range were ana-
lysed. Upon FGF-BP knockdown, markedly decreased
signal intensities were observed in Akt (pan), Akt1 and
Akt2, indicating reduced Akt signal transduction (Figure
4A, B). Results were confirmed by Western blotting
(Figure 4B, right panel). Notably, in contrast to previous
publications [39] no changes in ERK activation were
detected. On the other hand, activation upon FGF-BP
knockdown was determined in the case of GSK3b and
MSK2 and, to a lesser extent, in JNK (Figure 4A, B).
Other signal transduction molecules remained
unchanged or showed no significant difference.
Pro-apoptotic effects of FGF-BP knockdown are correlated
with alterations in molecules involved in apoptosis and
redox status
Since we found in this study an anti-apoptotic role of
FGF-BP, FGF-BP knockdown was also analysed with
regard to changes in molecules relevant in apoptosis.
Indeed, upon FGF-BP reduction a marked activation of
members of the bcl-2 family and promoters of apoptosis,
Bad and Bax, and to a lesser extent of bcl-2, was observed
in an apoptosis antibody array (Figure 5A, B). Further-
more, FGF-BP knockdown activated Trail receptors Trail
R1 and R2. Regarding proteins related to the redox status
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Page 7 of 15of the cells, a significant inhibition of catalase and a mod-
erate activation of HIF-1a was detected (Figure 5A, B).
For the general confirmation of the robustness of the anti-
body array results, these findings were reproduced by
Western blotting, indicating a similar inhibition of catalase
and a somewhat more pronounced activation of HIF-1a
(Figure 5B, right). Activation upon FGF-BP knockdown
was also detected for livin and PON2, while signals specific
for cleaved caspase-3 were reduced (Figure 5A). Finally,
p21 showed ~2-fold higher levels after FGF-BP inhibition
(Figure 5A, B; see also Figure 4B for Western blot confir-
mation), which is in line with the observed decrease in cell
cycle progression (see Figure 3A).
Analysis of cellular and molecular effects of FGF-BP
knockdown
To further analyse the role of downstream signal trans-
duction pathways on the observed FGF-BP knockdown
effects, stably FGF-BP shRNA-transfected p21-/- knock-
out cells were generated. In these cell lines, the prolif-
eration rate was independent of FGF-BP expression
levels (Figure 6A), which is in contrast to the p21 wt
cells (see Figure 2E). This indicates that anti-prolifera-
tive effects of the FGF-BP knockdown may be based on
the upregulation of p21 (see Figures 4B right, 5B cen-
ter), thus being dependent on the presence of p21
expression.
Based on its role in various pathways including ERK1/
2 activation, b-catenin signalling and c-Myc/cyclin D1
expression, previous studies have suggested a putative
role of GSK3b as a tumor suppressor [40]. Interestingly,
we observed that FGF-BP knockdown resulted in
GSK3b upregulation (see Figure 4), prompting us to
further study whether alterations in FGF-BP levels
would influence effects of GSK3b inhibition. Indeed,
while GSK3b inhibition by treatment of LS174T cells
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Page 8 of 15with 20 nM or 40 nM 6-bromoindirubin-3-oxime (BIO)
led to a > 2-fold induction of cell proliferation (Figure
6B, left), this effect was largely lost upon FGF-BP knock-
down (Figure 6B, right). Here, a statistically non-signifi-
cant increase in cell proliferation was only observed at
40 nM BIO, suggesting that the GSK3b upregulation
upon FGF-BP knockdown may attenuate the effects of
the inhibitor.
FGF-BP has been shown previously to exert its tumor-
promoting role through the activation of FGF2, and to
activate FGF2 [3,7]. To analyse whether FGF-BP influ-
ences FGF2-mediated stimulation of colon carcinoma
cells, mock transfected or FGF-BP shRNA-transfected
LS174T cells were treated with increasing amounts of
FGF2. While a dose-dependent stimulation of cell prolif-
eration was observed in the cells with high endogenous
FGF-BP expression (Figure 6C, left), this effect was com-
pletely abrogated after FGF-BP knockdown (Figure 6C,
right). This indicates that the cellular effects observed
upon FGF-BP knockdown are, at least in part, due to a
reduction in FGF2-mediated stimulation.
Finally, we analysed if tumor cell inhibition is also
obtained after a transient siRNA-mediated FGF-BP
knockdown, thus avoiding the generation of stable cell
lines with possible adaptation processes during the
selection procedure. Indeed, a statistically significant
reduction in HT29 cell proliferation was observed (Fig-
ure 6D). This also provided the basis for using siRNAs
in a therapeutic in vivo approach.
Anti-tumor effects of therapeutic FGF-BP knockdown in
vivo
To assess the therapeutic relevance of FGF-BP as a tar-
get for gene knockdown approaches, we employed a
polyethylenimine (PEI)-based delivery platform for siR-
NAs previously established in our lab [35,41] in order to
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Page 9 of 15induce RNAi in already established tumors. Subcuta-
neous tumor xenografts were generated by injecting wt
LS174T tumor cells and, upon formation of solid
tumors, mice were randomized and treated systemically
through intraperitoneal (i.p.) injection of PEI/siRNA
complexes. I.p. administration was preferred over i.v.
injection due to the more efficient siRNA delivery [35].
Although LS174T had been found to be rather hard to
transfect with PEI complexes in vitro (data not shown),
the analysis of the levels of [32P]-labeled, PEI com-
plexed siRNAs in vivo revealed the delivery of intact
siRNAs into the tumor (Figure 7B). For therapeutic
intervention, mice with established tumor xenografts
were treated three times per week as indicated in Figure
7A with PEI-complexed, FGF-BP-specific siRNAs. No
treatment or treatment with PEI-complexed, non-speci-
fic siRNAs at the same time points served as negative
controls. Upon termination of the experiment after 3
weeks of treatment, a ~ 40% reduced tumor growth was
observed in the FGF-BP-specific knockdown group (Fig-
ure 7A) as compared to the negative control treatment.
Due to their size, some tumors in the no treatment and
in the negative control treatment groups showed poor
tissue integrity with some wounding and a partial loss of
tumor mass already prior to the time point of termina-
tion of the experiment, which may rather lead to a slight
under-estimation of PEI/siRNA-mediated antitumor
effects (see Figure 7A, right, for some representative
examples). Concomitant with the observed reduction in
tumor growth, Western blotting of the tumor lysates
that were available for analysis revealed ~ 30% reduced
FGF-BP levels in the tumor xenografts of the specific
treatment group as compared to the controls, which
both showed identical levels (Figure 7C). From these
data we conclude that already a rather moderate ~ 30%
knockdown of FGF-BP exerts anti-tumor effects.
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Figure 5 Pro-apoptotic effects of FGF-BP knockdown are correlated with alterations in molecules involved in apoptosis and redox
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In this paper, we show that FGF-BP knockdown exerts
tumor-inhibiting effects in colon carcinoma in vitro and in
vivo, which are based on anti-proliferative as well as pro-
apoptotic effects in tumor cells. Our cell cycle experiments
demonstrate that anti-proliferative effects rely on a G0/G1
arrest leading to cell cycle prolongation. On a molecular
level, this involves the cell cycle control protein p21
WAF1/
CIP which is upregulated upon FGF-BP knockdown.
Usually, p21 acts as tumor suppressor that is p53-depen-
dently upregulated upon genotoxic effectors or cellular
stress [42]. Interestingly, in our system the induction of
p21 was independent of p53, since no changes in p53
activity (phosphorylation) were observed although LS174T
cells are p53 (+/+) [43]. This mechanism of p53-indepen-
dent induction of p21 has been described previously (see
e.g. [44]). The relevance of p21 in mediating FGF-BP
effects on proliferation is supported by the abrogation of
inhibitory effects of an FGF-BP knockdown on the prolif-
eration of p21 knockout cells shown here. Furthermore,
FGF-BP has been demonstrated to be involved in the cel-
lular signal transduction, leading to FGF-2 induced phos-
phorylation of ERK1/2 [3] and Akt [45]. It was also shown
that the overexpression of the positive FGF-BP regulator
KLF-5 leads to the activation of Akt kinases [46], which
have been described in several studies as relevant in colon
carcinoma tumorigenesis (see e.g. [47]). In cellular survival
signalling, Akt kinases play a pivotal role by (i) blocking
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Figure 6 Analysis of cellular and molecular effects of FGF-BP knockdown. The effects of FGF-BP levels on cell proliferation are dependent
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Page 11 of 15pro-apoptotic proteins [48], (ii) inhibiting the SAPK/JNK
pathway [49] and (iii) antagonizing p21 induction (see [50]
for review). Indeed, upon FGF-BP knockdown we
observed Akt suppression and activation of p21 (see
above), SAPK/JNK, caspases-3/7 and mediators of apopto-
sis, the cell death-enhancing BH3-only domain proteins
Bad and Bax. Another Akt antagonist in PI3K/Akt signal-
ling is GSK3, which is negatively regulated by Akt [51].
Concomitantly, we found that GSK3b is upregulated upon
FGF-BP knockdown. This is also in line with the observa-
tion that cultivation of cells under serum-free conditions
leads to increased GSK3 activity and apoptosis (see [52]
for review). This GSK3b upregulation also led to a reduced
sensitivity of FGF-BP shRNA-transfected cells towards the
GSK3b inhibitor 6-bromoindirubin-3-oxime (BIO). While
a recent study has described an attenuation of cell survival
and proliferation upon GSK3b inhibition [53], our data
rather support the notion of GSK3b acting as a tumor
suppressor [40].
It has been established previously that FGF-BP knock-
down leads to reduced bioactivation of FGFs from the
ECM and thus lower effective concentrations. Indeed,
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Page 12 of 15we show FGF-BP knockdown was able to abolish the
stimulatory effects of exogenous FGF2 in colon carci-
noma cells. Although this confirms the role of FGF-BP
in enhancing FGF activity, it does not exclude additional
mechanisms of action, as suggested e.g. by the presence
of FGF-BP in the nucleus of tumor cells (Aigner et al.,
unpublished data). While previous studies showed con-
tradictory results whether FGF-BP enhances the anti-
apoptotic effects of FGF-2 [45] or is not related to apop-
tosis [15], we clearly demonstrate in this paper the anti-
apoptotic function of human FGF-BP in tumor cells.
The fact that no additional anti-apoptotic effects are
observed in LS174T cells upon exogenous FGF-BP
transfection also suggests that a maximum threshold
level of FGF-BP in LS174T cells is already reached by
endogenous FGF-BP (over-)expression. Notably, the
induction of apoptosis upon FGF-BP knockdown also
coincides with the activation of cell death receptors
TrailR1 and TrailR2 (DR4 and DR5, respectively) and,
to a lesser extent, Fas/TNFR. This indicates apoptosis
activation through the extrinsic pathway, and the Bax
activation observed here suggests further signalling in a
‘type II cell’ manner (see [54] for review).
In FGF-BP knockdown cells, we also observed an
imbalance in the redox status. FGF-BP depletion led to
a modest decrease in catalase and modest increase in
HIF1a levels. It has been shown previously that in a
tumor, a number of compensatory mechanisms can
occur under hypoxic conditions (see [55] for review).
This includes an increased expression of pro-angiogenic
growth factors leading to angiogenesis/neo-vasculariza-
tion, and a cell matrix remodelling/increased heparan
sulphate proteoglycan synthesis that leads to higher
numbers of FGF2 binding sites and thus HIF1a-
mediated increase in FGF signalling [56]. This effect is
paralleled by an increase in NDST-1 activity [56] which
in turn positively influences FGF-BP expression [57].
Taken together, this indicates that FGF-BP is involved
in an autocrine regulation loop.
Additionally, alterations in Akt activity as shown
above may also interfere with cellular sensitivity towards
oxidative stress (’Akt-induces ROS-triggered cell death’).
More specifically, Nogueira et al. showed that, upon Akt
hyperactivation, cells are more prone to oxidative stress
and intracellular accumulation of ROS through
increased oxygen consumption and decreased expression
of ROS scavengers [58]. Beyond the direct pro-apoptotic
effects of ROS, this may be relevant for the sensitivity/
resistance towards certain cytostatics acting through
ROS generation. Notably, in our study decreased cata-
lase levels were observed upon FGF-BP knockdown,
suggesting impaired protection against oxidative stress.
While this supports again the pro-apoptotic effect of
FGF-BP inhibition, it also indicates that FGF-BP levels
may determine the sensitivity of tumor cells towards
chemotherapy. Indeed, this is observed for certain cyto-
statics dependent on their mechanism of action (Schulze
et al., manuscript in preparation). Taken together, our
data indicate that FGF-BP is integrated in a complex
network of cytoprotective effects.
The therapeutic relevance of our findings is demon-
strated by our in vivo data in mice. By employing
siRNA-loaded nanocarriers for a therapeutic in vivo
knockdown approach in established wildtype tumor
xenografts, this study goes beyond previous publications
based on ex vivo generated stable knockdown cell lines
that were s.c. injected and thus do not mimick a thera-
peutic situation [29]. In vivo studies using FGF-BP-spe-
cific siRNAs have so far been limited to microinjection
into chicken embryos in order to analyse the role of
chBP in embryo development [59] or the use of mor-
pholinos during zebrafish embryongenesis [60]. Here,
h o w e v e r ,w ee x p l o r ef o rt h ef i r s tt i m eat h e r a p e u t i c
FGF-BP knockdown approach in tumors. To this end,
we employ polymer-based nanoparticles which allow the
in vivo delivery of siRNAs upon their systemic applica-
tion ([35]; see [61] for review). Previous studies had
demonstrated the absence of non-specific effects (acute
toxicity, activation of immune responses, upregulation
of inflammatory cytokines) of the PEI/siRNA nanoparti-
cles [35]. In accordance with previous results [35], the
determination of the levels of [
32P]-labelled siRNAs
demonstrate efficient delivery of intact siRNAs into the
tumors. This is true even upon systemic administration
which is more relevant in a therapeutic setting than
local (intratumoral) injection. Concomitantly, a ~30%
knockdown of FGF-BP expression is observed which
proved sufficient for anti-tumor effects. This is in line
with previous findings in stable FGF-BP knockdown
prostate carcinoma cells, which showed an already com-
plete abrogation of tumor formation upon injection of
cells with 50% reduced FGF-BP levels [15], and further
supports the possible relevance of FGF-BP as a thera-
peutic target molecule.
Conclusions
Taken together, the knockdown of FGF-BP exerts multi-
ple cellular and molecular effects in colon carcinoma
including the induction of apoptosis, and FGF-BP repre-
sents a promising therapeutic target, for example by
RNAi-based knockdown approaches through delivery of
therapeutic siRNAs.
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